There is little doubt that progress in many brain diseases is being hampered because many, maybe most, diagnostic categories do not reflect underlying brain processes. In other disease areas, modern genetic and genomic methods have arrived in the form of approved drugs, from KRAS inhibitors in cancer to PCSK9 inhibitors to lower cholesterol. But brain diseases are different. Psychiatry is simultaneously the most personal area of medicine, and the least precise.
Compass Pathways Ltd. has joined with a U.K. hospital and an academic establishment to research the role of psychedelic medicine in new models of mental health care. The London-based company signed a memorandum of understanding with South London and Maudsley NHS Foundation Trust and the Institute of Psychiatry, Psychology and Neuroscience at King’s College London to launch the project.
DUBLIN – Compass Pathways Ltd. raised $80 million in a series B round to continue its development of the psychedelic drug psilocybin in treatment-resistant depression.